graph Evidence gap map comparisons
antibody–drug conjugate
sacituzumab govitecan
mBC-Triple negative (TNBC) - 2nd Line (L2) 3    
mBC - TNBC - L2 - all population 2
mBC - TNBC - L2 - PDL1 positive 2
Comparator:  vs Standard of Care (SoC); 
Risk of bias:  low;   some concerns;   high;  NA;